Effects of progesterone on ovarian tumorigenesis in xenografted mice

McDonnel, Anna C.; Kirk, Edward A. Van; Isaak, Dale D.; Murdoch, William J.

doi:10.1016/j.canlet.2004.09.011

Cited by 21 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deposits on the mesentery/intestines are more opposing than their hepatic cohorts which were negated by progesterone alone. Progesterone was ineffective once tumors were well established [11]; this is consistent with the general consensus that progestins are of limited benefit in the treatment of bulky disease [10].…”

Section: Discussionsupporting

confidence: 80%

“…This is the first report indicating that progesterone induces cisplatin toxicity in human ovarian adenocarcinoma cell lines (SKOV-3, OVCAR-3) and a preclinical murine xenograft (SKOV-3) model. Previously we found that progesterone suppressed tumorigenesis in athymic mice when administration was initiated prior to an ip inoculation of SKOV-3 cells [11]. Now it is evident that progesterone is of utility when applied after the formation of tumor colonies typical of metastatic-and recurrent-onset conditions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts

Murdoch

Kirk

Isaak

et al. 2008

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

Objectives-The underlying premise of these investigations was that the lipophilic hormone progesterone, which partitions into and (at relatively high concentrations) impedes the fluid mechanics of the plasmalemma, would perturb integral associations between membrane lipids and exporter pumps that otherwise confer drug resistance. That progesterone can affect susceptibility of ovarian adenocarcinoma cells and xenografts to cisplatin was tested.Methods-The cisplatin-resistant human cell lines SKOV-3 and OVCAR-3 were treated for 24 hours with cisplatin (0.1 μg/ml) ± progesterone (0.01, 0.1 μg/ml). Cytotoxicity and platinum were measured by MTT assay and inductively coupled plasma mass spectrometry, respectively. Athymic mice were inoculated intraperitoneal (ip) with SKOV-3 cells. Cisplatin (2 mg/kg/week) ± progesterone (25 mg sustained-release pellet) regimens were initiated ip at one week (when micrometastases were present) and continued to six weeks post-xenograft. Tumor burdens, histopathology, and platinum concentrations were assessed upon necropsy at 24 hours after the final injection of cisplatin.Results-There were no significant in vitro/vivo anticancer effects of cisplatin alone. High-dose progesterone enhanced platinum accretion and induced drug toxicity in both cell lines. Tumorigenesis was suppressed by cisplatin + progesterone. The treatment synergy was related to elevated tumor platinum and morphological evidence of apoptosis.Conclusion-It appears that the addition of progesterone to ovarian cancer therapeutic modalities represents a step in improving responses.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts

Murdoch

Kirk

Isaak

et al. 2008

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, some mice with E 2 pellets were also treated with 1 mg of P SC every day (P 4 , Dr. Carreras, Hospital 14) for 2 weeks within a 3-week interval (43). These dosages were chosen because previous studies demonstrated that they were able to sustain systemic E 2 and P 4 levels in cycling women (44,45).…”

Section: Xenotransplantation Assaysmentioning

confidence: 99%

Identification and characterization of the human leiomyoma side population as putative tumor-initiating cells

Mas

Cervelló

Gil-Sanchís

et al. 2012

Fertility and Sterility

101

105

View full text Add to dashboard Cite

“…It was demonstrated in several studies that tumor cells may be sensitized and subsequently destructed by this joint treatment (101,102). Obtained results suggest that the combined electric field and ultrasound therapy may provide a novel, drug-free modality for cancer treatment that might have a great perspective in the near future.…”

Section: Electrochemotherapymentioning

confidence: 90%

Physical mechanisms and methods employed in drug delivery to tumors

Bešić¹

2007

Acta Pharmaceutica

View full text Add to dashboard Cite

Physical mechanisms and methods employed in drug delivery to tumorsIn addition to several well-known drug delivery strategies developed to facilitate effective chemotherapy with anticancer agents, some new approaches have been recently established, based on specific effects arising from the applications of ultrasound, magnetic and electric fields on drug delivery systems. This paper gives an overview of newly developed methods of drug delivery to tumors and of the related anticancer therapies based on the combined use of different physical methods and specific drug carriers. The conventional strategies and new approaches have been put into perspective to revisit the existing and to propose new directions to overcome the threatening problem of cancer diseases.

show abstract

Effects of progesterone on ovarian tumorigenesis in xenografted mice

Cited by 21 publications

References 15 publications

Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts

Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts

Identification and characterization of the human leiomyoma side population as putative tumor-initiating cells

Physical mechanisms and methods employed in drug delivery to tumors

Contact Info

Product

Resources

About